Intravenous Immunoglobulin Therapy in the treatment of Moderate Pneumonia in COVID-19 patients : A Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

WHO International Clinical Trials Registry Platform - (2021) vom: 24. Nov. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Phase: Phase 2
Recruitment Status: Completed
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-06-2020, Last updated: 2022-11-24

ICTRP ID:

CTRI/2020/06/026222
VB-N-IVIG-COVID-19/2020-CT2
version 2 date 20.05.2020

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG00429646X